A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis

Inclusion Criteria: * Male or female patients aged between 19 and 65 years old * Clinical diagnosis of seborrheic dermatitis in the facial area with Erythema severity ≥ 2 and Scaling severity ≥ 2 * IGE (Investigator's Global Evaluation) Score 2 or 3 Exclusion Criteria: * Patients with psoriasis, atopic dermatitis, facial acne, rosacea or perioral dermatitis * Patients who have been infected with bacteria, fungi, virus and animal infectious disease on the facial area * Patients who were administered topical antifungal agents, steroids, retinoids, or calcineurin suppressants for the treatment of seborrheic dermatitis within the last 2 weeks * Patients who were administered systemic antifungal agents, steroids, retinoids, or immunosuppressants for the treatment of seborrheic dermatitis within the last 4 weeks * Patients who were administered local antibiotics for the treatment of seborrheic dermatitis within the last 4 weeks * Pregnant women, breastfeeding women or women of childbearing potential or women who are planning a pregnancy during the study